Agilent Technologies, Inc. $A Shares Acquired by Amundi

Amundi increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,110,095 shares of the medical research company’s stock after acquiring an additional 13,101 shares during the period. Amundi owned approximately 0.39% of Agilent Technologies worth $133,944,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Verdence Capital Advisors LLC lifted its position in shares of Agilent Technologies by 5.0% in the second quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company’s stock worth $215,000 after purchasing an additional 86 shares in the last quarter. M&T Bank Corp grew its stake in Agilent Technologies by 0.4% in the 2nd quarter. M&T Bank Corp now owns 23,205 shares of the medical research company’s stock valued at $2,738,000 after buying an additional 86 shares during the last quarter. CENTRAL TRUST Co increased its stake in shares of Agilent Technologies by 3.7% in the second quarter. CENTRAL TRUST Co now owns 2,522 shares of the medical research company’s stock worth $298,000 after purchasing an additional 89 shares during the period. Burney Co. increased its position in Agilent Technologies by 4.8% in the 2nd quarter. Burney Co. now owns 1,957 shares of the medical research company’s stock worth $231,000 after buying an additional 90 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its position in Agilent Technologies by 1.7% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,443 shares of the medical research company’s stock worth $760,000 after acquiring an additional 110 shares during the period.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. JPMorgan Chase & Co. increased their target price on Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. TD Cowen raised their price target on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Barclays boosted their price objective on Agilent Technologies from $145.00 to $165.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 25th. Finally, Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $161.08.

Insiders Place Their Bets

In other news, VP Rodney Gonsalves sold 3,000 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the sale, the vice president directly owned 31,846 shares in the company, valued at $4,935,811.54. This represents a 8.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Padraig Mcdonnell sold 12,490 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total value of $1,873,500.00. Following the transaction, the chief executive officer owned 33,448 shares in the company, valued at approximately $5,017,200. The trade was a 27.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,401 shares of company stock valued at $2,468,962 in the last ninety days.

Agilent Technologies Price Performance

Shares of A opened at $145.45 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. The stock has a market capitalization of $41.24 billion, a PE ratio of 31.83, a PEG ratio of 4.22 and a beta of 1.27. The company has a 50 day moving average price of $144.84 and a 200-day moving average price of $128.15. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.01. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The firm had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the previous year, the firm earned $1.46 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. Equities analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 6th will be issued a dividend of $0.255 per share. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend is Tuesday, January 6th. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s payout ratio is presently 21.66%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.